SL
ELDN icon

Siren LLC’s Eledon Pharmaceuticals ELDN Stock Holding History

Siren LLC’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,072,767
Closed -$5.37M – 117
2025
Q3 		$5.37M Buy
2,072,767
+1,382,597
+200% +$4.04M 0.21% 62
2025
Q2 		$1.87M Hold
690,170
– – 0.1% 84
2025
Q1 		$2.34M Buy
+690,170
New +$2.84M 0.13% 79

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $712M AUM
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
ZP
Zimmer Partners New York $4.15B AUM 14.2% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Siren LLC's ELDN Position: Q4 2025 in Review

Siren LLC sold out of Eledon Pharmaceuticals (ELDN) in Q4 2025, closing a stake of 2,072,767 shares — an estimated $5.37M sold.

Siren LLC first reported a position in ELDN in Q1 2025 and held it in 3 quarters. The position peaked at $5.37M in Q3 2025. 95 funds tracked by Wall St. Rank hold ELDN as of Q4 2025.

  • Siren LLC reported no remaining Eledon Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Siren LLC sold 2,072,767 Eledon Pharmaceuticals shares in Q4 2025, an estimated $5.37M.
  • Siren LLC first reported a position in Eledon Pharmaceuticals in Q1 2025 and held it in 3 quarters.
  • Siren LLC's Eledon Pharmaceuticals position peaked at $5.37M in Q3 2025.
  • 95 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q4 2025.

Based on Siren LLC's 13F filing for Q4 2025, filed 13 Feb 2026.